Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven W Lane

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysisElda Righi, Anna Maria Peri, Patrick N A Harris, et al.
STAR Protocols|July 1, 2026
LOTR-Seq: A protocol for large-scale simultaneous single-cell long-read genotyping of transcriptsJulian Grabek, Leanne Cooper, Rohit Haldar, et al.
Plos One|June 18, 2015
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or LeukemiaSara Charmsaz, Kirrilee Beckett, Fiona M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
CNS relapse in acute promyeloctyic leukemiaElizabeth Housman, Priscilla Chang, Steven W Lane, et al.
Annals of Hematology|April 11, 2008
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patientsSaar Gill, Steven W Lane, Julie Crawford, et al.
Cell Stem Cell|April 10, 2012
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CMLFlorian H Heidel, Lars Bullinger, Zhaohui Feng, et al.
Leukemia & Lymphoma|October 27, 2006
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancySteven W Lane, Julie Crawford, Melita Kenealy, et al.
Blood|December 13, 2012
Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacyMiranda A Coleman, Jennifer A Bridge, Steven W Lane, et al.
Internal Medicine Journal|November 10, 2018
Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasmsCecily J Forsyth, Wai-Hoong Chan, Andrew P Grigg, et al.
Haematologica|May 28, 2017
Acute myeloid leukemia stem cell function is preserved in the absence of autophagyAmy H Porter, Lucie Leveque-El Mouttie, Therese Vu, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysisElda Righi, Anna Maria Peri, Patrick N A Harris, et al.
STAR Protocols|July 1, 2026
LOTR-Seq: A protocol for large-scale simultaneous single-cell long-read genotyping of transcriptsJulian Grabek, Leanne Cooper, Rohit Haldar, et al.
Plos One|June 18, 2015
EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or LeukemiaSara Charmsaz, Kirrilee Beckett, Fiona M Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
CNS relapse in acute promyeloctyic leukemiaElizabeth Housman, Priscilla Chang, Steven W Lane, et al.
Annals of Hematology|April 11, 2008
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patientsSaar Gill, Steven W Lane, Julie Crawford, et al.
Cell Stem Cell|April 10, 2012
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CMLFlorian H Heidel, Lars Bullinger, Zhaohui Feng, et al.
Leukemia & Lymphoma|October 27, 2006
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancySteven W Lane, Julie Crawford, Melita Kenealy, et al.
Blood|December 13, 2012
Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacyMiranda A Coleman, Jennifer A Bridge, Steven W Lane, et al.
Internal Medicine Journal|November 10, 2018
Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasmsCecily J Forsyth, Wai-Hoong Chan, Andrew P Grigg, et al.
Haematologica|May 28, 2017
Acute myeloid leukemia stem cell function is preserved in the absence of autophagyAmy H Porter, Lucie Leveque-El Mouttie, Therese Vu, et al.
Pageof 11